title: Remission maintenance therapy in acute myelogenous leukemia.
abstract: Because no conclusive evidence as to the efficacy of maintenance chemotherapy in acute myelogenous leukemia (AML) existed, a study to obtain such information was done. Twenty-six adult patients with AML in whom complete remission had been achieved following induction chemotherapy were randomly assigned to receive either maintenance chemotherapy consisting of cytarabine and 6-thioguanine for two days each month or to receive no maintenance therapy. The data showed a significant difference in remission duration between the two groups, with median remission lengths for the maintained and unmaintained groups being 10.3 and 6.7 months, respectively (p<.05). In 46 percent of the maintained patients there were remissions lasting longer than 11 months, whereas in none of the unmaintained patients was there such a prolonged remission. No significant drug-induced toxicity was observed. That the prolonged exposure to these chemotherapeutic agents, which were also used in our induction program, did not adversely affect the rate of successful reinduction therapy was shown by identical 50 percent complete remission rates for second inductions in both groups. In patients with palpable splenomegaly at the time of diagnosis, there was no prolongation of remission with maintenance therapy. These data indicate the potential utility of maintenance chemotherapy for prolonging remission duration in acute myelogenous leukemia.
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D003561:Cytarabine / Q000627:therapeutic use; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008875:Middle Aged; D012075:Remission, Spontaneous; D013866:Thioguanine / Q000627:therapeutic use
chemical_list: D003561:Cytarabine; D013866:Thioguanine
references.citation: Lancet. 1975 Oct 4;2(7936):621-4
references.pmid: 52000
references.citation: N Engl J Med. 1976 Jan 8;294(2):75-80
references.pmid: 53787
references.citation: JAMA. 1976 Mar 8;235(10):1021-5
references.pmid: 946184
references.citation: Cancer. 1975 Aug;36(2):775-95
references.pmid: 1057450
references.citation: Br J Haematol. 1976 Feb;32(2):145-9
references.pmid: 1061617
references.citation: Cancer. 1975 Sep;36(3):855-60
references.pmid: 1182675
references.citation: Cancer Res. 1972 Dec;32(12):2593-607
references.pmid: 4118763
references.citation: Lancet. 1973 Mar 10;1(7802):534-8
references.pmid: 4119962
references.citation: JAMA. 1968 May 13;204(7):574-9
references.pmid: 4296700
references.citation: Calif Med. 1972 Dec;117(6):1-11
references.pmid: 4508367
references.citation: Cancer. 1972 Dec;30(6):1572-82
references.pmid: 4509106
references.citation: Cancer. 1973 Aug;32(2):286-93
references.pmid: 4516214
references.citation: Semin Hematol. 1974 Jan;11(1):25-39
references.pmid: 4520529
references.citation: Arch Intern Med. 1974 Feb;133(2):260-6
references.pmid: 4521468
references.citation: Cancer. 1974 Feb;33(2):427-34
references.pmid: 4521471
references.citation: Blood. 1974 Sep;44(3):375-83
references.pmid: 4527645
references.citation: Blood. 1968 Oct;32(4):507-23
references.pmid: 4879053
references.citation: Presse Med. 1970 Jan 31;78(6):253-6
references.pmid: 4984925
references.citation: Cancer. 1969 May;23(5):1019-32
references.pmid: 5252232
references.citation: Nat New Biol. 1971 Sep 22;233(38):109-10
references.pmid: 5285962
references.citation: Cancer Chemother Rep. 1967 Jun;51(3):125-65
references.pmid: 6043735
references.citation: Cancer Chemother Rep. 1964 Nov;42:25-8
references.pmid: 14226126
references.citation: Biometrika. 1965 Jun;52:203-23
references.pmid: 14341275
references.citation: J Clin Invest. 1967 Aug;46(8):1356-63
references.pmid: 16695924